[1] [1] WHO. Draft working document for comments: development of paediatric medicines points to consider in formulation[EB/OL]. [2025-03-10]. https://cdn.who.int/media/docs/default-source/medicines/norms-and-standards/current-projects/qas24.950_paediatric_medicines.pdf?sfvrsn=59fed2f_1.

[2] [2] FDA. Oral solutions and suspensions (8/94). Guide to inspections oral solutions and suspensions [EB/OL]. (2014-11-17)[2025-03-10]. https://www.fda.gov/inspectionscompliance-enforcement-and-criminal-investigations/inspection-guides/oral-solutions-and-suspensions-894

[5] [5] FDA. Nasal spray and inhalation solution, suspension, and spray drug products —chemistry, manufacturing, and controls documentation [EB/OL]. [2025-03-10]. https://www.fda.gov/regulatory-information/search-fda-guidancedocuments/nasal-spray-and-inhalation-solution-suspensionand-spray-drug-products-chemistry-manufacturing-and.

[7] [7] EMA. Note for guidance on excipients, antioxidants andantimicrobial preservatives in the dossier forapplication for marketing authorisation of amedicinal product [EB/OL]. (2003-02-20) [2025-03-10]. https://www.ema.europa.eu/en/documents/scientific-guideline/draft-note-guidance-excipients-antioxidants-antimicrobial-preservatives-dossierapplication_en.pdf.

[8] [8] EMA. Tamiflu: EPAR-scientific discussion [EB/OL]. (2005-10-21) [2025-06-20]. https://www.ema.europa.eu/en/documents/scientific-discussion/tamiflu-epar-scientific-discussion_en.pdf.

[9] [9] MAHESWARAN R. FDA Perspectives: scientific considerations offorced degradation studies in ANDA submissions [J].Pharm Tech, 2012,36(5): 73-80.

[11] [11] FDA. Compilation of FDA guidance and resources forin vitrodissolution testing of immediate release solid oral dosage forms [EB/OL]. (2025-02-20)[2025-03-10]. https://www.fda.gov/animal-veterinary/new-animal-drug-applications/compilation-fda-guidance-and-resources-in-vitro-dissolutiontesting-immediate-release-solid-oral-dosage.

[12] [12] ICH. M9: Biopharmaceutics classification system-based biowaivers and Q & As on biopharmaceutics classification system-based biowaivers [EB/OL]. (2019-11-20) [2025-03-10]. https://www.ich.org/page/multidisciplinaryguidelines.

[13] [13] ANAND O, YU L X, CONNER D P,et al. Dissolution testing for generic drugs an FDA perspective [J].AAPS J, 2011,13(3): 328-335.

[14] [14] SIEWERT M, DRESSMAN J, BROWN C K,et al. FIP/AAPS guidelines to dissolution/in vitrorelease testing of novel/special dosage forms [J].AAPS PharmSciTech, 2003,4.

[15] [15] FDA. Specific product guidance: draft guidance on posaconazole oral suspension [EB/OL]. [2025-03-10]. https://www.https://www.accessdata.fda.gov/drugsatfda_docs/psg/Posaconazole_Susp_22003_RC 11-07.pdf.

[16] [16] FDA. Specific product guidance: methylphenidate hydrochloride_draft_oral suspension [EB/OL]. [2025-03-10]. https://www.accessdata.fda.gov/drugsatfda_docs/psg/Methylphenidate%20Hydrochloride_draft_Oral%20suspER_RLD%20202100_RC12-14.pdf.

[18] [18] WHO. QAS_Dissolution_test_for_solid_oral_dosage_forms[EB/OL]. (2020-06)[2025-03-10]. https://www.who.int/docs/default-source/medicines/norms-and-standards/current-projects/qas20-837-dissolution-test-for-solid-oral-dosage-forms.pdf.

[21] [21] EMA. Reflection paper on the dissolution specification for generic-solid oral immediate release products with systemic action [EB/OL]. (2017-07) [2025-03-10]. https://www.tga.gov.au/resources/resource/international-scientificguidelines/reflection-paper-dissolution-specificationgeneric-solid-oral-immediate-release-products-systemicaction#: ~: text=Reflection-paper-on-the-dissolution-specification-for-generic-solid-oral-immediate-release-products-with-systemic-action%20%5BPDF%2C%20156.9%20KB%5D%20Adopted, by%20the%20TGA%3A%208%20June%202023.

[22] [22] FDA. Dissolution methods database frequently asked questions [EB/OL]. (2022-03-01) [2025-06-20]. https://www.fda.gov/drugs/development-resources/dissolution-methods-database-frequently-asked-questions#7.

[24] [24] FDA. LRB QbR for oral solutions and suspensions [EB/OL]. (2021-05-06) [2025-03-10]. https://www.fda.gov/drugs/how-drugs-are-developed-and-approved/lrb-qbr-oral-solutions-and-suspensions.